Effects of GH in women with abdominal adiposity: A 6-month randomized, double-blind, placebo-controlled trial

European Journal of Endocrinology

Volumn 166, Issue 4, 2012, Pages 601-611

  Bredella, Miriam A ^a   Lin, Eleanor ^a   Brick, Danielle J ^a   Gerweck, Anu V ^a   Harrington, Lindsey M ^a   Torriani, Martin ^a   Thomas, Bijoy J ^a   Schoenfeld, David A ^a   Breggia, Anne ^b   Rosen, Clifford J ^b   Hemphill, Linda C ^a   Wu, Zida ^c   Rifai, Nader ^d   Utz, Andrea L ^e   Miller, Karen K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Maine Medical Center Research Institute   (United States)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; C REACTIVE PROTEIN; GROWTH HORMONE; LOW DENSITY LIPOPROTEIN; PLACEBO; SOMATOMEDIN C; TISSUE PLASMINOGEN ACTIVATOR;

ABDOMINAL OBESITY; ABDOMINAL SUBCUTANEOUS FAT; ADULT; ARTERIAL WALL THICKNESS; ARTICLE; BODY COMPOSITION; BODY FAT DISTRIBUTION; CARDIOVASCULAR RISK; CELL FUNCTION; CONTROLLED STUDY; DISEASE MARKER; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; ENDOTHELIUM CELL; FEMALE; GLUCOSE BLOOD LEVEL; HORMONE ACTION; HUMAN; INTRAABDOMINAL FAT; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; MUSCLE MASS; OUTCOME ASSESSMENT; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TRUNK;

ABDOMINAL FAT; ADIPOSITY; ADOLESCENT; ADULT; BIOLOGICAL MARKERS; BODY COMPOSITION; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; DOUBLE-BLIND METHOD; FEMALE; HUMAN GROWTH HORMONE; HUMANS; MIDDLE AGED; OBESITY; PLACEBOS; RISK FACTORS; SEX FACTORS; TIME FACTORS; YOUNG ADULT;

EID: 84859415664     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-11-1068     Document Type: Article

References (44)

1. Grundy SM. Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation 2002 105 2696-2698. (doi:10.1161/01. CIR.0000020650.86137.84)
2. Rexrode KM, Carey VJ, Hennekens CH, Walters EE, Colditz GA, Stampfer MJ, Willett WC & Manson JE. Abdominal adiposity and coronary heart disease in women. Journal of the American Medical Association 1998 280 1843-1848. (doi:10.1001/jama.280.21. 1843)
3. Pijl H, Langendonk JG, Burggraaf J, Frolich M, Cohen AF, Veldhuis JD & Meinders AE. Altered neuroregulation of GH secretion in viscerally obese premenopausal women. Journal of Clinical Endocrinology and Metabolism 2001 86 5509-5515. (doi:10.1210/jc.86.11.5509)
4. Utz AL, Yamamoto A, Hemphill L & Miller KK. Growth hormone deficiency by growth hormone releasing hormone-arginine testing criteria predicts increased cardiovascular risk markers in normal young overweight and obese women. Journal of Clinical Endocrinology and Metabolism 2008 93 2507-2514. (doi:10. 1210/jc.2008-0169)
5. Weaver JU, Monson JP, Noonan K, John WG, Edwards A, Evans KA & Cunningham J. The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity, and cardiovascular risk factors in hypopituitary adults. Journal of Clinical Endocrinology and Metabolism 1995 80 153-159. (doi:10.1210/jc.80.1.153)
6. Vahl N, Jorgensen JO, Skjaerbaek C, Veldhuis JD, Orskov H & Christiansen JS. Abdominal adiposity rather than age and sex predicts mass and regularity of GH secretion in healthy adults. American Journal of Physiology 1997 272 E1108-E1116.
7. Beauregard C, Utz AL, Schaub AE, Nachtigall L, Biller BM, Miller KK & Klibanski A. Growth hormone decreases visceral fat and improves cardiovascular risk markers in women with hypopituitarism: a randomized, placebo-controlled study. Journal of Clinical Endocrinology and Metabolism 2008 93 2063-2071. (doi:10.1210/jc.2007-2371)
8. Sesmilo G, Biller BM, Llevadot J, Hayden D, Hanson G, Rifai N & Klibanski A. Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Annals of Internal Medicine 2000 133 111-122. (Pubitemid 30490411)
9. Rudling M & Angelin B. Loss of resistance to dietary cholesterol in the rat after hypophysectomy: importance of the presence of growth hormone for hepatic low density lipoprotein-receptor expression. PNAS 1993 90 8851-8855. (doi:10.1073/pnas.90.19.8851)
10. Bredella MA, Torriani M, Thomas BJ, Ghomi RH, Brick DJ, Gerweck AV & Miller KK. Peak growth hormone-releasing hormone-arginine-stimulated growth hormone is inversely associated with intramyocellular and intrahepatic lipid content in premenopausal women with obesity. Journal of Clinical Endocrinology and Metabolism 2009 94 3995-4002. (doi:10.1210/jc.2009-0438)
11. Rommel C, Bodine SC, Clarke BA, Rossman R, Nunez L, Stitt TN, Yancopoulos GD & Glass DJ. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/ Akt/GSK3 pathways. Nature Cell Biology 2001 3 1009-1013. (doi:10.1038/ncb1101-1009)
12. Baum HB, Biller BM, Finkelstein JS, Cannistraro KB, Oppenhein DS, Schoenfeld DA, Michel TH, Wittink H & Klibanski A. Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled trial. Annals of Internal Medicine 1996 125 883-890.
13. Franco C, Brandberg J, Lonn L, Andersson B, Bengtsson BA & Johannsson G. Growth hormone treatment reduces abdominal visceral fat in postmenopausal women with abdominal obesity: a 12-month placebo-controlled trial. Journal of Clinical Endocrinology and Metabolism 2005 90 1466-1474. (doi:10.1210/jc.2004- 1657)
14. Johannsson G, Marin P, Lonn L, Ottosson M, Stenlof K, Bjorntorp P, Sjostrom L & Bengtsson BA. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. Journal of Clinical Endocrinology and Metabolism 1997 82 727-734. (doi:10.1210/jc.82.3.727)
15. Pasarica M, Zachwieja JJ, Dejonge L, Redman S & Smith SR. Effect of growth hormone on body composition and visceral adiposity in middle-aged men with visceral obesity. Journal of Clinical Endocrinology and Metabolism 2007 92 4265-4270. (doi:10.1210/jc.2007-0786)
16. Tomlinson JW, Crabtree N, Clark PM, Holder G, Toogood AA, Shackleton CH & Stewart PM. Low-dose growth hormone inhibits 11 beta-hydroxysteroid dehydrogenase type 1 but has no effect upon fat mass in patients with simple obesity. Journal of Clinical Endocrinology and Metabolism 2003 88 2113-2118. (doi:10.1210/jc.2002-021894)
17. Han TS, van Leer EM, Seidell JC & Lean ME. Waist circumference action levels in the identification of cardiovascular risk factors: prevalence study in a random sample. BMJ 1995 311 1401-1405. (doi:10.1136/bmj.311.7017.1401)
18. Lean ME, Han TS & Morrison CE. Waist circumference as a measure for indicating need for weight management. BMJ 1995 311 158-161. (doi:10.1136/bmj.311.6998.158)
19. Bredella MA, Ghomi RH, Thomas BJ, Torriani M, Brick DJ, Gerweck AV, Misra M, Klibanski A & Miller KK. Comparison of DXA and CT in the assessment of body composition in premenopausal women with obesity and anorexia nervosa. Obesity 2010 18 2227-2233. (doi:10.1038/oby.2010.5)
20. Bredella MA, Hosseini Ghomi R, Thomas BJ, Miller KK & Torriani M. Comparison of 3.0 T proton magnetic resonance spectroscopy short and long echo-time measures of intramyocellular lipids in obese and normal-weight women. Journal of Magnetic Resonance Imaging 2010 32 388-393. (doi:10.1002/jmri.22226)
21. Bredella MA, Hosseini Ghomi R, Thomas BJ, Ouellette HA, Sahani DV, Miller KK & Torriani M. Breath-hold 1H-magnetic resonance spectroscopy for intrahepatic lipid quantification at 3 Tesla. Journal of Computer Assisted Tomography 2010 34 372-376. (doi:10.1097/RCT.0b013e3181cefb89)
22. Bredella MA, Torriani M, Hosseini Ghomi R, Thomas BJ, Brick DJ, Gerweck AV, Rosen CJ, Klibanski A & Miller KK. Vertebral bone marrow fat is positively associated with visceral fat and inversely associated with IGF-1 in obese women. Obesity 2011 19 49-53. (doi:10.1038/oby.2010.106)
23. Bredella MA, Utz AL, Torriani M, Thomas B, Schoenfeld DA & Miller KK. Anthropometry CT and DXA as predictors of GH deficiency in premenopausal women: ROC curve analysis. Journal of Applied Physiology 2009 106 418-422. (doi:10.1152/japplphysiol.90998.2008)
24. Lukaski HC. Methods for the assessment of human body composition: traditional and new. American Journal of Clinical Nutrition 1987 46 537-556. (Pubitemid 18005716)
25. Cunningham JJ. Calculation of energy expenditure from indirect calorimetry: assessment of the Weir equation. Nutrition 1990 6 222-223. (Pubitemid 20300194)
26. Miller KK, Wexler T, Fazeli P, Gunnell L, Graham GJ, Beauregard C, Hemphill L, Nachtigall L, Loeffler J, Swearingen B, Biller BM & Klibanski A. Growth hormone deficiency after treatment of acromegaly: a randomized, placebo-controlled study of growth hormone replacement. Journal of Clinical Endocrinology and Metabolism 2010 95 567-577. (doi:10.1210/jc.2009-1611)
27. Hamburg NM, Keyes MJ, Larson MG, Vasan RS, Schnabel R, Pryde MM, Mitchell GF, Sheffy J, Vita JA & Benjamin EJ. Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham Heart Study. Circulation 2008 117 2467-2474. (doi:10.1161/CIRCULATIONAHA.107.748574)
28. Wu Z, Bidlingmaier M, Dall R & Strasburger CJ. Detection of doping with human growth hormone. Lancet 1999 353 895. (doi:10. 1016/S0140-6736(99) 00775-8)
29. Bidlingmaier M, Suhr J, Ernst A, Wu Z, Keller A, Strasburger CJ & Bergmann A. High-sensitivity chemiluminescence immunoassays for detection of growth hormone doping in sports. Clinical Chemistry 2009 55 445-453. (doi:10.1373/clinchem.2008. 112458)
30. Bengtsson BA, Eden S, Lonn L, Kvist H, Stokland A, Lindstedt G, Bosaeus I, Tolli J, Sjostrom L & Isaksson OG. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. Journal of Clinical Endocrinology and Metabolism 1993 76 309-317. (doi:10.1210/jc.76.2.309)
31. Rosen T & Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990 336 285-288. (doi:10.1016/0140-6736(90) 91812-O)
32. Maison P, Griffin S, Nicoue-Beglah M, Haddad N, Balkau B & Chanson P. Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a metaanalysis of blinded, randomized, placebo-controlled trials. Journal of Clinical Endocrinology and Metabolism 2004 89 2192-2199. (doi:10. 1210/jc.2003-030840)
33. Despres JP, Lemieux I & Prud'homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ 2001 322 716-720. (doi:10.1136/bmj.322.7288.716)
34. Burman P, Johansson AG, Siegbahn A, Vessby B & Karlsson FA. Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women. Journal of Clinical Endocrinology and Metabolism 1997 82 550-555. (doi:10.1210/jc.82.2.550)
35. Munzer T, Harman SM, Hees P, Shapiro E, Christmas C, Bellantoni MF, Stevens TE, O'Connor KG, Pabst KM, St Clair C, Sorkin JD & Blackman MR. Effects of GH and/or sex steroid administration on abdominal subcutaneous and visceral fat in healthy aged women and men. Journal of Clinical Endocrinology and Metabolism 2001 86 3604-3610. (doi:10.1210/jc.86.8.3604)
36. Fidler MC, Sanchez M, Raether B, Weissman NJ, Smith SR, Shanahan WR & Anderson CM. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. Journal of Clinical Endocrinology and Metabolism 2011 96 3067-3077. (doi:10.1210/jc.2011-1256)
37. James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, Torp-Pedersen C, Sharma AM, Shepherd GM, Rode RA & Renz CL. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. New England Journal of Medicine 2010 363 905-917. (doi:10.1056/NEJMoa1003114)
38. Fowelin J, Attvall S, Lager I & Bengtsson BA. Effects of treatment with recombinant human growth hormone on insulin sensitivity and glucose metabolism in adults with growth hormone deficiency. Metabolism 1993 42 1443-1447. (doi:10.1016/ 0026-0495(93)90197-V)
39. Svensson J, Fowelin J, Landin K, Bengtsson BA & Johansson JO. Effects of seven years of GH-replacement therapy on insulin sensitivity in GH-deficient adults. Journal of Clinical Endocrinology and Metabolism 2002 87 2121-2127. (doi:10.1210/jc.87.5. 2121)
40. Hoffman AR, Kuntze JE, Baptista J, Baum HB, Baumann GP, Biller BM, Clark RV, Cook D, Inzucchi SE, Kleinberg D, Klibanski A, Phillips LS, Ridgway EC, Robbins RJ, Schlechte J, Sharma M, Thorner MO & Vance ML. Growth hormone (GH) replacement therapy in adult-onset GH deficiency: effects on body composition in men and women in a double-blind, randomized, placebocontrolled trial. Journal of Clinical Endocrinology and Metabolism 2004 89 2048-2056. (doi:10.1210/jc.2003-030346)
41. Ho KK, O'Sullivan AJ & Hoffman DM. Metabolic actions of growth hormone in man. Endocrine Journal 1996 43 (Suppl) S57-S63. (doi:10.1507/endocrj. 43.Suppl-S57)
42. Krusenstjerna-Hafstrom T, Clasen BF, Moller N, Jessen N, Pedersen SB, Christiansen JS & Jorgensen JO. Growth hormone (GH)-induced insulin resistance is rapidly reversible: an experimental study in GH-deficient adults. Journal of Clinical Endocrinology and Metabolism 2011 96 2548-2557. (doi:10. 1210/jc.2011-0273)
43. Moller N & Jorgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocrine Reviews 2009 30 152-177. (doi:10.1210/er.2008-0027)
44. Krag MB, Gormsen LC, Guo Z, Christiansen JS, Jensen MD, Nielsen S & Jorgensen JO. Growth hormone-induced insulin resistance is associated with increased intramyocellular triglyceride content but unaltered VLDL-triglyceride kinetics. American Journal of Physiology. Endocrinology and Metabolism 2007 292 E920-E927. (doi:10.1152/ajpendo.00374.2006)